# A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer

Source: https://onco.cc/trials/nct06313983/  
OnCo record `nct06313983` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Capecitabine and Lapatinib in advanced solid tumours, run by Tianjin Hemay Pharmaceutical Co., Ltd, now recruiting.

## Summary

A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer is a phase 3 interventional study registered as NCT06313983 by Tianjin Hemay Pharmaceutical Co., Ltd, with 339 participants planned, started 2022-01-08 and due to reach its primary completion in 2025-12. Interventions recorded: Hemay022+AI and Lapatinib+Capecitabine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06313983
- Phase: 3
- Setting: A Phase Ⅲ Randomized, Open Label, Parallel, Multicenter To Assess Efficacy and Safety Study of Hemay022 in Combination With AI In Postmenopausal HER2+/ER+ Advanced Breast Cancer Patients Treated With Trastuzumab-containing Regimens
- Sponsor: Tianjin Hemay Pharmaceutical Co., Ltd
- Enrolled: 339

## Sources

- ClinicalTrials.gov NCT06313983: https://clinicaltrials.gov/study/NCT06313983

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Lapatinib](https://onco.cc/drugs/lapatinib/)

---
JSON: https://onco.cc/api/v1/entities/nct06313983.json